Sripathi M Sureban

Contact Information:
Sripathi M Sureban


Sureban, Sripathi M. (HSC)

Department of:

College Of Medicine/Medicine - Gastroenterology -Assistant Professor of Research

Center of:

Peggy & Charles Stephenson Oklahoma Cancer Center -Associate Member


Bangalore University   Bachelor in Pharmacology   1997
Rajiv Gandhi University of Health Sciences   Master in Pharmacy (Pharmacognosy)   1999
University of Madras, Department of Medical Microbiology   Ph.D.   2004

Professional Interest/Expertise/Specializations:
I have a broad background in colorectal cancer, pancreatic cancer and stem cells. As a postdoctoral fellow at Washington University School of Medicine, I carried out research investigating the role of RNA binding proteins (RBM3, CUGBP2 and HuR) in colorectal cancer. At the University of Oklahoma Health Sciences Center, initially as a postdoctoral fellow and now as assistant professor of research, I expanded my research to identify, isolate and characterize stem cells of intestine, pancreas, colon and stomach. In collaboration with Dr. Houchen, we have demonstrated that DCLK1 (formerly known as DCAMKL-1) is upregulated in various cancers including colorectal, pancreas, breast liver and prostate. DCLK1 regulates various tumor suppressor miRNAs, which in turn regulates key oncogenes and transcription factors regulating epithelial to mesenchymal transition (EMT), pluripotency, angiogenesis and metastasis. Currently I am working towards elucidating the mechanism by which RNA binding protein Musashi-1 (Msi-1) regulates tumor growth. It has been demonstrated by our group that Msi-1 is upregulated in colorectal cancer and siRNA mediated knockdown leads to colorectal tumor xenograft growth arrest in immunocompromised mice by inhibiting cancer cell proliferation and inducing mitotic catastrophe. Furthermore, we have recently found that Msi-1 regulates key tumor suppressor miRNAs like Let-7a, miR-144 and miR-200a. These tumor suppressor miRNAs are known to regulate oncogene c-Myc, KRAS, Notch-1 and EMT transcription factors. Our research is also focused on developing nanoparticle formulations for effective delivery of siRNA against Msi-1.


Department of Internal Medicine-Faculty Listing
Department of Internal Medicine-Section of Digestive Diseases and Nutrition
Peggy and Charles Stephenson Oklahoma Cancer Center

Research Projects:

1) Isolation and Characterization of Intestinal Stem Cells Using Novel Markers (NIH/NIDDK) 9/09 - 8/14 [Role - Key Personal] [Courtney W. Houchen - PI]
2) Tuft cell regulation of miRNAs in Pancreatic Cancer (DOD-CDMRP) 10/12 - 6/14 [Role - Key Personal] [Courtney W. Houchen - PI]
3) Development of monoclonal antibodies to treat Pancreatic cancer (NIH/SBIR) 07/13 - 02/14 [Role - Key Personnel - OUHSC Sub-contract] [Panayotis Pantazis - PI]

Selected Publications:

Dietary Pectin Increases Intestinal Crypt Stem Cell Survival following Radiation Injury.
2015    Sureban SM, May R, Qu D, Chandrakesan P, Weygant N, Ali N, Lightfoot SA, Ding K, Umar S, Schlosser MJ, Houchen CW
PLoS One. 2015 Aug 13;10(8):e0135561. doi: 10.1371/journal.pone.0135561. eCollection 2015 PMID: 26270561
Inflammatory and oncogenic roles of a tumor stem cell marker doublecortin-like kinase (DCLK1) in virus-induced chronic liver diseases.
2015    Ali N, Chandrakesan P, Nguyen CB, Husain S, Gillaspy AF, Huycke M, Berry WL, May R, Qu D, Weygant N, Sureban SM, Bronze MS, Dhanasekaran DN, Houchen CW
Oncotarget. 2015 Aug 21;6(24):20327-44 PMID: 25948779
DCLK1 is a broadly dysregulated target against epithelial-mesenchymal transition, focal adhesion, and stemness in clear cell renal carcinoma
2015    Weygant N, Qu D, May R, Tierney RM, Berry WL, Zhao L, Agarwal S, Chandrakesan P, Chinthalapally HR, Murphy NT, Li JD, Sureban SM, Schlosser MJ, Tomasek JJ, Houchen CW
Oncotarget. 2015 Feb 10;6(4):2193-205. PMID: 25605241[]=3059
Ablation of Doublecortin-Like Kinase 1 in the Colonic Epithelium Exacerbates Dextran Sulfate Sodium-Induced Colitis.
2015    Qu D, Weygant N, May R, Chandrakesan P, Madhoun M, Ali N, Sureban SM, An G, Schlosser MJ, Houchen CW
PLoS One. 2015 Aug 18;10(8):e0134212. doi: 10.1371/journal.pone.0134212. eCollection 2015 PMID:26285154
Plasma DCLK1 is a marker of hepatocellular carcinoma (HCC): Targeting DCLK1 prevents HCC tumor xenograft growth via a microRNA-dependent mechanism.
2015    Sureban SM, Madhoun MF, May R, Qu D, Ali N, Fazili J, Weygant N, Chandrakesan P, Ding K, Lightfoot SA, Houchen CW
Oncotarget. 2015 Nov 10;6(35):37200-15. doi: 10.18632/oncotarget.5808 PMID:26468984[]=5808&pubmed-linkout=1
Regulation of miRNAs by agents targeting the tumor stem cell markers DCLK1, MSI1, LGR5, and BMI1.
2015    Sureban SM, Qu D, Houchen CW
Curr Pharmacol Rep. 2015 Aug 1;1(4):217-222 PMID: 26366338
Dclk1+ small intestinal epithelial tuft cells display the hallmarks of quiescence and self-renewal.
2015    Chandrakesan P, May R, Qu D, Weygant N, Taylor VE, Li JD, Ali N, Sureban SM, Qante M, Wang TC, Bronze MS, Houchen CW
Oncotarget. 2015 Oct 13;6(31):30876-86. doi: 10.18632/oncotarget.5129 PMID: 26362399[]=5129&pubmed-linkout=1
Doublecortin-like kinase 1 is elevated serologically in pancreatic ductal adenocarcinoma and widely expressed on circulating tumor cells
2015    Qu D, Johnson J, Chandrakesan P, Weygant N, May R, Aiello N, Rhim A, Zhao L, Zheng W, Lightfoot S, Pant S, Irvan J, Postier R, Hocker J, Hanas JS, Ali N, Sureban SM, An G, Schlosser MJ, Stanger B, Houchen CW
PLoS One. 2015 Feb 27;10(2):e0118933. eCollection 2015. PMID: 25723399
DCLK1 is detectable in plasma of patients with Barrett's esophagus and esophageal adenocarcinoma
2015    Whorton J, Sureban SM, May R, Qu D, Lightfoot SA, Madhoun M, Johnson M, Tierney WM, Maple JT, Vega KJ, Houchen CW
Dig Dis Sci. 2015 Feb;60(2):509-13. Epub 2014 Oct 5. PMID: 25283374
Brief report: Dclk1 deletion in tuft cells results in impaired epithelial repair after radiation injury
2014    May R, Qu D, Weygant N, Chandrakesan P, Ali N, Lightfoot SA, Li L, Sureban SM, Houchen CW
Stem Cells. 2014 Mar;32(3):822-7. PMID: 24123696
XMD8-92 inhibits pancreatic tumor xenograft growth via a DCLK1-dependent mechanism
2014    Sureban SM, May R, Weygant N, Qu D, Chandrakesan P, Bannerman-Menson E, Ali N, Pantazis P, Westphalen CB, Wang TC, Houchen CW
Cancer Lett. 2014 Aug 28;351(1):151-61. Epub 2014 May 28. PMID: 24880079
Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1.
2014    Weygant N, Qu D, Berry WL, May R, Chandrakesan P, Owen DB, Sureban SM, Ali N, Janknecht R, Houchen CW
Mol Cancer. 2014 May 6;13:103. PMID: 24885928
DCLK1 facilitates intestinal tumor growth via enhancing pluripotency and epithelial mesenchymal transition
2014    Chandrakesan P, Weygant N, May R, Qu D, Chinthalapally HR, Sureban SM, Ali N, Lightfoot SA, Umar S, Houchen CW
Oncotarget. 2014 Oct 15;5(19):9269-80. PMID: 25211188
Inhibition of Notch signaling reduces the number of surviving Dclk1+ reserve crypt epithelial stem cells following radiation injury
2014    Qu D, May R, Sureban SM, Weygant N, Chandrakesan P, Ali N, Li L, Barrett T, Houchen CW.
Am J Physiol Gastrointest Liver Physiol. 2014 Mar 1;306(5):G404-11. PMID: 24368703
DCLK1 regulates pluripotency and angiogenesis via microRNA dependent mechanisms in pancreatic cancer
2013    Sureban, S.M., Qu, D., May, R., Ali, N., Chandrakesan, P., Weygant, N., Lightfoot, S.A., Pantazis, P., Brackett, D.J., Rao, C.V., Postier, R.G. and Houchen, C.W
PLoS One. 2013 Sep 9;8(9):e73940. PMID: 24040120
Epigenetic variation of stem cell markers in cancer
2013    Sureban, S.M., Qu, D., and Houchen, C.W.
Invited Book Chapter-Epigenetics and Cancer-115-128. Springer Netherlands
Fluvastatin interferes with hepatitis C virus replication via microtubule bundling and a doublecortin-like kinase-mediated mechanism
2013    Ali N, Allam H, Bader T, May R, Basalingappa KM, Berry WL, Chandrakesan P, Qu D, Weygant N, Bronze MS, Umar S, Janknecht R, Sureban SM, Huycke M, Houchen CW
PLoS One. 2013 Nov 19;8(11):e80304. PMID: 24260365